Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

BACKGROUND: Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR-T790M mutation (T790M). We sought to describe T790M changes in serum/plasma during osimertinib therapy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Morán, Teresa, Felip, Eudald, Bosch-Barrera, Joaquim, de Aguirre, Itziar, Ramirez, Jose Luis, Mesia, Carles, Carcereny, Enric, Roa, Diana, Sais, Elia, García, Yolanda, Blanco, Remei, Sanchez, Silvia, Villacorta, Claudia Rosa, Queralt, Cristina, Velarde, Jose María, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007479/
https://www.ncbi.nlm.nih.gov/pubmed/29930751
http://dx.doi.org/10.18632/oncotarget.25478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007479/
https://www.ncbi.nlm.nih.gov/pubmed/29930751
http://dx.doi.org/10.18632/oncotarget.25478

Ejemplares similares